Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Method optimization for the quantification of the NAD metabolome in human whole blood, and evaluation of baseline inter and intra-subject variability.
Whole blood from healthy participants will be collected to optimize analytical method based on liquid chromatography tandem mass spectrometry (LC-MS/MS) for the analysis of the NAD metabolome in biological samples. Parameters such as collection volume and anti-coagulants will be investigated for optimal quantification. Moreover, inter- and intra-subject variability of NAD metabolite levels in whole blood will be evaluated. Plasma and urine will also collected for method development and variability measurements.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Laboratory method validation | Other | Test several sampling conditions |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of NAD metabolite concentrations in whole blood, collected with different tubes and anticoagulants. | NAD metabolites in whole blood will be quantified by liquid chromatography-tandem | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Estimation of inter- and intra-subject variabilities of NAD metabolites in whole blood | Descriptive estimates of the inter and intra subjects variances will be calculated with the standard formulas. | through study completion, an average of 1 year |
| Validation of the method for a set of NAD metabolites in plasma and urine (including determination of Limit Of Detection-LOD, Limit Of Quantification- LOQ). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Healthy volunteers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Cuenoud Bernard | Nestle Health Science | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Innovation Lab. | Lausanne | Switzerland |
Not provided
Not provided
Not provided
Not provided
NAD metabolites in urine and in blood will be quantified to enable to measure several validation parameters, such as intra and interday precision, LOD, LOQ, r2. |
| through study completion, an average of 1 year |